TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05581043

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3-hydroxybutyrate (3-OHB)
Description: The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate (3-OHB)
Description: The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate (3-OHB)
Description: The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate (3-OHB)
Description: The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate (3-OHB)
Description: The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate (3-OHB)
Description: The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).
Study: NCT04725656

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Smoking cessation counseling at baseline, week 1, and week 4.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Smoking cessation counseling at baseline, week 1, and week 4.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Smoking cessation counseling
Description: Smoking cessation counseling at baseline, week 1, and week 4.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open system vape device and nicotine salt e-liquids
Description: Ad libitum use of nicotine salt e-liquids during three months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open system vape device and nicotine salt e-liquids
Description: Ad libitum use of nicotine salt e-liquids during three months.
Study: NCT05178537

Intervention type: OTHER
Intervention: AAS users
Description: no intervention
Study: NCT06219538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAISY Uterine Drain
Description: Insertion of the DAISY Uterine Drain and connection to wall suction in women who have undergone a Caesarean Delivery.
Study: NCT04847271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity on prescription (PAP)
Description: The intervention in this study will comprise the 3 PAP components. Participants will take part in all components and perform one or several physical activities of their choice in accordance to the written prescription, at the prescribed frequency and duration, for a period of 4 months.
Study: NCT06233292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG005 Powder for Injection
Description: The dose groups of ZG005 for dose escalations are set as 0.3 mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, and 20mg/kg, intravenous infusion, once every 3 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG005 Powder for Injection
Description: Recommended Phase 2 Dose (RP2D) of ZG005 monotherapy, intravenous infusion, once every 3 weeks.
Study: NCT05707676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB4330
Description: LB4330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB4330
Description: LB4330
Study: NCT05796661

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effects of increased blood flow during regional anticoagulation with 4% trisodium citrate in patients undergoing continuous venovenous hemodiafiltration
Description: Patients will be exposed to continuous venovenous renal therapy with distinct blood flows in 2 periods, to be defined by draw. The control group will have a flow of 150ml/min and the intervention group 250ml/min. Therapy is intended for a period of 72 hours (maximum defined by the manufacturer); with a 6-hour washout and, after that, the arm is changed to be exposed to the other blood flow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects of increased blood flow during regional anticoagulation with 4% trisodium citrate in patients undergoing continuous venovenous hemodiafiltration
Description: Patients will be exposed to continuous venovenous renal therapy with distinct blood flows in 2 periods, to be defined by draw. The control group will have a flow of 150ml/min and the intervention group 250ml/min. Therapy is intended for a period of 72 hours (maximum defined by the manufacturer); with a 6-hour washout and, after that, the arm is changed to be exposed to the other blood flow.
Study: NCT05050214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Each patient will be treated for 1 month and received a total of 3 doses. The first dose of Obinutuzumab (1000 mg) will be split in two separate infusions; on the first day each patient will receive 100 mg and the next day 900 mg of Obinutuzumab. Obinutuzumab (1000 mg) will be also administered at two and four weeks after the first infusion. Obinutuzumab will be administered after standard premedication.
Study: NCT05291884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella BTR
Description: Subjects will be prepared for pump insertion procedure according to clinical site standard of care. Procedural preparations for insertion of the Impella BTR are identical to the insertion of the Impella 5.0/5.5 via the axillary artery. The Impella BTR remains in situ until the patient is sufficiently recovered for removal or is transitioned to another form of support. It is expected that the Impella BTR is in situ for a maximum of 28 days.
Study: NCT06355713

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic resonance imaging- Positron Emission Tomography (MRI-PET) examination
Description: An MRI-PET examination will be carried out pre-operatively and at 6 months for the first 20 patients with Essure® and pre-operatively for the first 10 control patients presenting the selection criteria.~The duration of each acquisition will be approximately 2 hours. Upon arrival, participants will be greeted by electroradiography technicians. A venous catheter will be placed in a vein in the right or left arm. Participants will be installed in the hybrid MRI-PET imager. The injection of \[11C\]PK11195 will take place in the MRI-PET acquisition room. Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]PK11195 and will last for 70 minutes in a resting state.~At the end of the examination, the venous catheter will be removed and the visit will be over.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging- Positron Emission Tomography (MRI-PET) examination
Description: An MRI-PET examination will be carried out pre-operatively and at 6 months for the first 20 patients with Essure® and pre-operatively for the first 10 control patients presenting the selection criteria.~The duration of each acquisition will be approximately 2 hours. Upon arrival, participants will be greeted by electroradiography technicians. A venous catheter will be placed in a vein in the right or left arm. Participants will be installed in the hybrid MRI-PET imager. The injection of \[11C\]PK11195 will take place in the MRI-PET acquisition room. Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]PK11195 and will last for 70 minutes in a resting state.~At the end of the examination, the venous catheter will be removed and the visit will be over.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: Patients with Essure : Blood sample pre-operatively (20 mL) and at 2 months (10 mL) and 12 months (5 mL).~Control patients : Blood sample pre-operatively (20 mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Patients with Essure : Blood sample pre-operatively (20 mL) and at 2 months (10 mL) and 12 months (5 mL).~Control patients : Blood sample pre-operatively (20 mL)
Study: NCT06234267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat, Play, Sleep
Description: The Eat, Play, Sleep study will test health promotion text messages developed following guidelines for text message program development, aligned with established recommendations for diet, physical activity, and sleep in cancer survivorship and prevention. Feasibility of text message delivery and acceptability of the text message content related to dietary quality, physical activity, and sleep hygiene health behaviors will be tested in delivery to participants (cancer survivor/caregiver dyads) who indicate difficulty engaging in dietary quality, physical activity, or sleep hygiene behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat, Play, Sleep
Description: The Eat, Play, Sleep study will test health promotion text messages developed following guidelines for text message program development, aligned with established recommendations for diet, physical activity, and sleep in cancer survivorship and prevention. Feasibility of text message delivery and acceptability of the text message content related to dietary quality, physical activity, and sleep hygiene health behaviors will be tested in delivery to participants (cancer survivor/caregiver dyads) who indicate difficulty engaging in dietary quality, physical activity, or sleep hygiene behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat, Play, Sleep
Description: The Eat, Play, Sleep study will test health promotion text messages developed following guidelines for text message program development, aligned with established recommendations for diet, physical activity, and sleep in cancer survivorship and prevention. Feasibility of text message delivery and acceptability of the text message content related to dietary quality, physical activity, and sleep hygiene health behaviors will be tested in delivery to participants (cancer survivor/caregiver dyads) who indicate difficulty engaging in dietary quality, physical activity, or sleep hygiene behaviors.
Study: NCT06355713

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: urine collection
Description: Patients with Essure : urine collection pre-operatively (10 mL) and at 2 months (10 mL) and 12 months (10 mL).~Control patients : urine collection pre-operatively (10 mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine collection
Description: Patients with Essure : urine collection pre-operatively (10 mL) and at 2 months (10 mL) and 12 months (10 mL).~Control patients : urine collection pre-operatively (10 mL)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Collection of a lock of hair
Description: Patients with Essure : Collection of a lock of hair pre-operatively and at 12 months Control patients : Collection of a lock of hair pre-operatively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collection of a lock of hair
Description: Patients with Essure : Collection of a lock of hair pre-operatively and at 12 months Control patients : Collection of a lock of hair pre-operatively

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire
Description: Questionnaires pre-operatively (except PGI-I) and at 2, 6, 12 months then twice a year up to 5 years for patients with Essure, and pre-operatively (except PGI-I) and at 2 months for control patients :~* PGI-I: symptom improvement score~* SF-12: quality of life with physical and mental dimension.~* FIQ: quality of life of women with fibromyalgia symptoms~* HADS: anxiety and depressive dimension~* MFI-20: fatigue according to 5 dimensions )~* VAS : pain assessment~* QDSA: assessment of sensory and emotional impact of pain~* FSFI : quality of sexual life~* Higham score

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: Questionnaires pre-operatively (except PGI-I) and at 2, 6, 12 months then twice a year up to 5 years for patients with Essure, and pre-operatively (except PGI-I) and at 2 months for control patients :~* PGI-I: symptom improvement score~* SF-12: quality of life with physical and mental dimension.~* FIQ: quality of life of women with fibromyalgia symptoms~* HADS: anxiety and depressive dimension~* MFI-20: fatigue according to 5 dimensions )~* VAS : pain assessment~* QDSA: assessment of sensory and emotional impact of pain~* FSFI : quality of sexual life~* Higham score
Study: NCT06206980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion
Description: This intervention includes a hospital-based and a home-based intervention. During the hospital stay, the patients were provided with a health education which included information about pneumonia pathophysiology, healthy-lifestyle habits, benefits of being physically active, and any questions patients may have would be answered.~Additionally, an exercise program is provided, which includes resistance and aerobic exercise.~At the end of the hospital stay, a diary is provided to patients for recording the physical activity that performing the following 3 months. This diary is accompanied by phone calls at 15 days, 1 and 2 months of the hospital stay. During the phone calls, patients are motivated to increase their activity levels, and any questions patients may have, are answered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional
Study: NCT04702100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrument assisted soft tissue mobilization
Description: the patients will receive instrument-assisted soft tissue mobilization:The subject was seated in a relaxed sitting position. M2T blade was used to find specific areas of restriction on RT upper trapezius. Then treatment plane 1 - 2 and 3 were used.The lubricant (Vaseline) was applied to the skin around the neck area prior to treatment and the tool was cleaned with an alcohol preparation pad. Then by using M2T blade with angle 45, we were giving long slow strokes without causing any discomfort or pain over muscle starting from its insertion up to its origin approximately for 2 to 3 min repeated two times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated neuromuscular inhibition technique
Description: will receive integrated neuromuscular inhibition technique: from supine lying position.we the patients will perform ischemic compression at trigger points then positional release technique and finally muscle energy technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: the patients will receive hot back for 10 minutes, active range of motion exercise, chin tuck, stretches

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: the patients will receive hot back for 10 minutes, active range of motion exercise, chin tuck, stretches

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: the patients will receive hot back for 10 minutes, active range of motion exercise, chin tuck, stretches
Study: NCT05584826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: On 2 separate treatment visits, participants will receive dosing of 100 mg MDMA HCl (\~84 mg MDMA) + 40 mg MDMA HCl (\~34 mg MDMA) supplement unless tolerability issues arise from the first dose or the participant declines
Study: NCT06001580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR101
Description: BR101 injection was administered once for 28 days observation period and then weekly until the subject experienced unacceptable toxicity, disease progression, poor compliance, pregnancy, informed withdrawal, death, study interruption, and withdrawal from the study
Study: NCT05918510

Intervention type: DIAGNOSTIC_TEST
Intervention: Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx
Description: The prospective observational study involves the collection of tissue, blood and saliva samples from OPSCC and occult T patients for detection of HPV-DNA/RNA, miRNA and mutation profile from DNA with centralized analysis of samples at IRCCS Regina Elena National Cancer Institute.

Intervention type: DIAGNOSTIC_TEST
Intervention: Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx
Description: The prospective observational study involves the collection of tissue, blood and saliva samples from OPSCC and occult T patients for detection of HPV-DNA/RNA, miRNA and mutation profile from DNA with centralized analysis of samples at IRCCS Regina Elena National Cancer Institute.
Study: NCT04967690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-053
Description: SI-053 will be used as an add-on to SoC for newly diagnosed GBM.In conjunction with surgical resection, SI-053 will be applied intracranially (i.c.) into the cavity that is formed after tumor resection. Post-operative chemoradiotherapy (including concomitant and adjuvant TMZ or following the CeTeG protocol) will be initiated at least 21 and no later than 35 days after SI-053 administration.
Study: NCT04752280

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton irradiation
Description: proton irradiation applied as follows: 30 x 2 Gy(RBE) 33 x 1,8 Gy (RBE), or 15 x 2,67 Gy (RBE)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon irradiation
Description: proton irradiation applied as follows: 30 x 2 Gy 33 x 1,8 Gy, or 15 x 2,67 Gy
Study: NCT04196374

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genomic Sequencing
Description: Whole Genome Sequencing and reporting of actionable genomic results for genes included on the ACMG secondary findings list.
Study: NCT05681403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Improved BEAM regimen
Description: Mitoxantrone hydrochloride liposome, carmostine, etoposide and cytarabine will be used as conditioning regimen for ASCT in the lymphoma patients.
Study: NCT04827290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-AGE diet
Description: Low-AGE diet during 24 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-AGE diet
Description: High-AGE diet during 24 months
Study: NCT05515029

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor
Description: Cyclophosphamide 100 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +45, +60, +90, +120 Vedolizumab 10 mg/kg/day, max. 300 mg on the days -1, +14, +28
Study: NCT05165875

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone-Lidocaine
Description: Intervention will be done on the same day based on the randomization.~For the steroid injection group, a 1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants.

Intervention type: OTHER
Group type: OTHER
Intervention: Splint
Description: Intervention will be done on the same day based on the randomization. For the splint group, a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks. Subsequently, the splint will be weaned and passive range of motion exercises taught.~For both groups, routine analgesia is not prescribed but the use is not restricted to the participants.
Study: NCT05853978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSS Plus
Description: BSS PLUS® Sterile Intraocular Irrigating Solution (balanced salt solution enriched with bicarbonate, dextrose, and glutathione)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BSS
Description: BSS® Sterile Irrigating Solution (balanced salt solution)
Study: NCT06129695

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Zygomatic implants
Description: the ideal way to support implant-based restorative procedures for full and partially edentulous patients who are missing bone in the upper posterior maxilla.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zygomatic implants
Description: the ideal way to support implant-based restorative procedures for full and partially edentulous patients who are missing bone in the upper posterior maxilla.
Study: NCT06393127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 Formulation C2
Description: BI 1015550 Formulation C2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 Formulation C2
Description: BI 1015550 Formulation C2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 Formulation C1
Description: BI 1015550 Formulation C1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 Formulation C1
Description: BI 1015550 Formulation C1
Study: NCT06198426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI3004
Description: IBI3004 will be administered. The Dose Limiting Toxicity (DLT) will be observed in the first treatment cycle. After completion of the DLT observation period, subjects will continue to receive IBI3004 until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.